N-甲氧基-N-甲基噻唑-5-甲酰胺 | 898825-89-3

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 中文名称: N-甲氧基-N-甲基噻唑-5-甲酰胺
• 英文名称: N-methoxy-N-methylthiazole-5-carboxamide
• 英文别名: N-Methoxy-N-methyl-1,3-thiazole-5-carboxamide
• CAS: 898825-89-3
• 化学式: C₆H₈N₂O₂S
• 分子量: 172.208
• InChiKey: OHCWGRKUQDBZNM-UHFFFAOYSA-N

物化性质

• 熔点：
  54-56
• 沸点：
  329.8±15.0 °C(Predicted)
• 密度：
  1.287±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  0.8
• 重原子数：
  11
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.33
• 拓扑面积：
  70.7
• 氢给体数：
  0
• 氢受体数：
  4

安全信息

• 危险品标志：
  Xi
• 海关编码：
  2934100090

SDS

Material Safety Data Sheet

---

Section 1. Identification of the substance
Product Name: N-Methoxy-N-methyl thiazole-5-carboxamide
Synonyms: N-Methoxy-N-methyl 5-thiazolecarboxamide

---

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.

---

Section 3. Composition/information on ingredients.
Ingredient name: N-Methoxy-N-methyl thiazole-5-carboxamide
CAS number: 898825-89-3

---

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

---

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

---

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

---

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Store in closed vessels.
Storage:

---

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

---

Section 9. Physical and chemical properties
Appearance: Not specified
Boiling point: No data
No data
Melting point:
Flash point: No data
Density: No data
Molecular formula: C6H8N2O2S
Molecular weight: 172.2

---

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, nitrogen oxides, sulfur oxides.

---

Section 11. Toxicological information
No data.

---

Section 12. Ecological information
No data.

---

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

---

Section 14. Transportation information
Non-harzardous for air and ground transportation.

---

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  N-甲氧基-N-甲基噻唑-5-甲酰胺 以 四氢呋喃 为溶剂， 反应 0.5h， 生成 5-噻唑基乙酮
  参考文献：
  名称：

  WO2006/76529

  摘要：

  公开号：
• 作为产物：
  描述：

  噻唑-5-甲酸 、 N-甲基-N-甲氧基胺盐酸盐 在 O-(1H-benzotriazol-1-yl)-N,N,N',N'-tetramethyluronium hexafluorophosphate 、 N,N-二异丙基乙胺 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 反应 16.0h， 以65%的产率得到N-甲氧基-N-甲基噻唑-5-甲酰胺
  参考文献：
  名称：

  WO2006/76529

  摘要：

  公开号：

文献信息

• TETRAHYDROPYRROLOTHIAZINE COMPOUNDS
  申请人：ELI LILLY AND COMPANY

  公开号：US20130261111A1

  公开（公告）日：2013-10-03

  The present invention provides compounds of Formula I: wherein A is selected from the group consisting of; R 1 is H or F; R 2 is H, —CH 2 OH, C 1 -C 3 alkyl, R 3 is H, F, or CN; R 4 is H, F; or CN; and R 5 is H, —CH 3 , or —OCH 3 ; or a pharmaceutically acceptable salt thereof.

  本发明提供了以下式I的化合物： 其中A选自以下组合之一； R1为H或F； R2为H，—CH2OH，C1-C3烷基， R3为H，F或CN； R4为H，F；或CN；和 R5为H，—CH3，或—OCH3； 或其药学上可接受的盐。
• [EN] HEPATITIS B CORE PROTEIN ALLOSTERIC MODULATORS<br/>[FR] MODULATEURS ALLOSTÉRIQUES DES PROTÉINES DU NOYAU DE L'HÉPATITE B
  申请人：UNIV INDIANA RES & TECH CORP

  公开号：WO2015138895A1

  公开（公告）日：2015-09-17

  ABSTRACT The present disclosure provides, in part, compounds having allosteric effector properties against Hepatitis B virus Cp. Also provided herein are methods of treating viral infections, such as hepatitis B, comprising administering to a patient in need thereof a disclosed compound.

  摘要 本公开提供了部分具有对乙型肝炎病毒Cp具有变构效应的化合物。本文还提供了治疗病毒感染（如乙型肝炎）的方法，包括向需要的患者施用所述化合物。
• Saturated Bioisosteres of <i>ortho</i> ‐Substituted Benzenes
  作者：Aleksandr Denisenko、Pavel Garbuz、Svetlana V. Shishkina、Nataliya M. Voloshchuk、Pavel K. Mykhailiuk

  DOI：10.1002/anie.202004183

  日期：2020.11.9

  Saturated bioisosteres of ortho‐disubstituted benzenes (bicyclo[2.1.1]hexanes) were synthesized, characterized and validated. These cores were incorporated into the bioactive compounds Valsartan, Boskalid and Fluxapyroxad instead of the benzene ring. The saturated analogues showed a similar level of antifungal activity compared to that of Boskalid and Fluxapyroxad.

  合成，表征和验证了邻二取代苯（双环[2.1.1]己烷）的饱和生物等排体。这些核心被并入了生物活性化合物Valsartan，Boskalid和Fluxapyroxad，而不是苯环。饱和类似物显示出与Boskalid和Fluxapyroxad相似的抗真菌活性。
• [EN] BENZENE SULFONAMIDES AS CCR9 INHIBITORS<br/>[FR] BENZÈNE-SULFONAMIDES À TITRE D'INHIBITEURS DE CCR9
  申请人：NORGINE BV

  公开号：WO2015097122A1

  公开（公告）日：2015-07-02

  The present invention relates to compounds useful as CCR9 modulators, to compositions containing them, to methods of making them, and to methods of using them. In particular, the present invention relates to compounds capable of modulating the function of the CCR9 receptor by acting as partial agonists, antagonists or inverse agonists. Such compounds may be useful to treat, prevent or ameliorate a disease or condition associated with CCR9 activation, including inflammatory and immune disorder diseases or conditions such as inflammatory bowel diseases (IBD).

  本发明涉及作为CCR9调节剂有用的化合物，包含这些化合物的组合物，制备它们的方法，以及使用它们的方法。具体而言，本发明涉及能够通过作为部分激动剂、拮抗剂或逆激动剂来调节CCR9受体功能的化合物。这些化合物可能有助于治疗、预防或缓解与CCR9激活相关的疾病或状况，包括炎症和免疫性疾病或状况，如炎症性肠病（IBD）。
• METHYLENE LINKED QUINOLINYL MODULATORS OF RORyt
  申请人：Janssen Pharmaceutica NV

  公开号：US20140107094A1

  公开（公告）日：2014-04-17

  The present invention comprises compounds of Formula I. wherein: R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , R 8 , and R 9 are defined in the specification. The invention also comprises a method of treating or ameliorating a syndrome, disorder or disease, wherein said syndrome, disorder or disease is rheumatoid arthritis or psoriasis. The invention also comprises a method of modulating RORγt activity in a mammal by administration of a therapeutically effective amount of at least one compound of claim 1.

  本发明包括以下式的化合物：其中：R1、R2、R3、R4、R5、R6、R7、R8和R9在规范中定义。该发明还包括一种治疗或改善综合症、疾病或疾病的方法，其中所述综合症、疾病或疾病是类风湿性关节炎或牛皮癣。该发明还包括通过给哺乳动物施用至少一种权利要求1中的化合物的治疗有效量来调节RORγt活性的方法。